Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

8.51

Today's Change

+0.815 (10.58%)

Day's Change

7.88 - 8.81

Trading Volume

3,698,669

Overview

Market Cap

2 Billion

Shares Outstanding

315 Million

Avg Volume

1,559,134

Avg Price (50 Days)

6.58

Avg Price (200 Days)

4.07

PE Ratio

-53.31

EPS

-0.16

Earnings Announcement

22-Nov-2024

Previous Close

7.70

Open

7.89

Day's Range

7.88 - 8.81

Year Range

0.975 - 8.81

Trading Volume

3,712,445

Price Change Highlight

1 Day Change

10.91%

5 Day Change

13.87%

1 Month Change

39.31%

3 Month Change

76.08%

6 Month Change

185.62%

Ytd Change

304.74%

1 Year Change

605.79%

3 Year Change

537.31%

5 Year Change

469.33%

10 Year Change

469.33%

Max Change

469.33%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment